Amply Discovery Limited

This project is focused on the discovery and preclinical validation of first-in-class drug candidates for the treatment of Triple Negative Breast Cancer (TNBC) based on a novel approach to identifying novel genetic targets. TNBC is a high-risk malignancy with a high unmet need. TNBC grows and spreads faster than other invasive breast cancer subtypes, has ...

AMPLY Discovery, using its proprietary AI-based technology platform, has established a pipeline of new, naturally occurring bioactive molecules designed to target complex bacterial infections. AMPLY's drug candidates show strong in vitro efficacy and excellent toxicity and bioavailability profiles. This project is focused on the preclinical validation of ...

This project is focused on the discovery of first-in-class drug candidates for the treatment of Acute Myeloid Leukaemia (AML) based on a novel approach to identifying novel genetic targets. AML is a high-risk hematologic malignancy with a high unmet need. Limited treatment options exist, particularly for patients who are ineligible for intensive chemother...

This project is focused on the discovery of best-in-class antimicrobial peptides (AMPs) and the preclinical validation of these new biologic molecules as an effective treatment alternative for multi-drug resistant tuberculosis (MDR-TB). Tuberculosis is a common bacterial infection, typically affecting the lungs, spread through inhalation of tiny droplets ...